For US Healthcare Professionals

For US HCPs

Order Now
Order Now
Order Now

DOSING AND ADMINISTRATION

Dose and Schedule1

  • BOOSTRIX is administered intramuscularly as a 0.5 mL dose
  • An initial dose of BOOSTRIX is administered 5 years or more after the last dose of the Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) series or 5 years or more after a dose of Tetanus and Diphtheria Toxoids Adsorbed (Td)
  • BOOSTRIX may be administered as an additional dose 9 years or more after the initial dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)
  • BOOSTRIX may be administered for tetanus prophylaxis for wound management. For management of a tetanus-prone wound, a dose of BOOSTRIX may be administered if at least 5 years have elapsed since previous receipt of a tetanus toxoid-containing vaccine
  • To prevent pertussis in infants younger than 2 months of age, administer BOOSTRIX to pregnant individuals during the third trimester of pregnancy
  • The use of BOOSTRIX as a primary series or to complete the primary series for diphtheria, tetanus, or pertussis has not been established

Dosage Forms and Strengths1

  • BOOSTRIX is an injectable suspension. Each dose is 0.5 mL

BOOSTRIX comes with a 2D barcode

  • 2D barcodes contain the vaccine name, manufacturer, National Drug Code (NDC) numbers, lot number, and expiration date
  • With 2D barcodes, you can update your inventory management system, patient records, and vaccination reports automatically, reducing the need for manual data entry if you have the correct scanner, hardware, and software

Preparation for Administration1

  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use the vaccine if either of these conditions exist. Shake vigorously to obtain a homogeneous, turbid, white suspension before administration. Do not use if resuspension does not occur with vigorous shaking
  • For the prefilled syringes, attach a sterile needle and administer intramuscularly
  • For the vials, use a sterile needle and sterile syringe to withdraw the 0.5-mL dose and administer intramuscularly
CPT® code2: 90715
BOOSTRIX is a registered trademark of the GSK group of companies.
CPT is a registered trademark of the American Medical Association.

Indication & Important Safety Info

Indication

Important Safety Information

Indication

BOOSTRIX is indicated for:

  • active booster immunization against tetanus, diphtheria, and pertussis in individuals aged 10 years and older;
  • immunization during the third trimester of pregnancy to prevent pertussis in infants younger than 2 months of age. 

Important Safety Information

  • Contraindications for BOOSTRIX are: a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine; and encephalopathy within 7 days of administration of a previous dose of a pertussis antigen-containing vaccine
  • Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of BOOSTRIX
  • The decision to give BOOSTRIX should be based on benefits and risks if Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior tetanus toxoid-containing vaccine
  • Progressive or unstable neurologic conditions are reasons to defer vaccination with a pertussis-containing vaccine, including BOOSTRIX
  • Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of tetanus toxoid-containing vaccine should not receive BOOSTRIX unless 10 years have elapsed since the last dose of a tetanus toxoid-containing vaccine
  • Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to BOOSTRIX
  • Syncope (fainting) may occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting
  • Common solicited adverse reactions (≥15%) in adolescents (aged 10 to 18 years) were pain, redness, and swelling at the injection site; increase in arm circumference of the injected arm; headache; fatigue; and gastrointestinal symptoms
  • Common solicited adverse reactions (≥15%) in adults (aged 19 to 64 years) were pain, redness, and swelling at the injection site; headache; fatigue; and gastrointestinal symptoms
  • The most common solicited adverse reaction (≥15%) in the elderly (aged 65 years and older) was pain at the injection site
  • Pregnancy: Available data from a controlled clinical study showed that the use of the non-U.S. formulation of BOOSTRIX* during the third trimester of pregnancy did not reveal any vaccine-related adverse effects on pregnancy or on the fetus/newborn child
  • Pregnancy Registry: HCPs are encouraged to register pregnant individuals by calling 1-888-452-9622 or visiting http://pregnancyregistry.gsk.com/boostrix.html
  • Vaccination with BOOSTRIX may not result in protection in all vaccine recipients

 

* The non-U.S. formulation of BOOSTRIX is manufactured to contain 0.5 mg aluminum per dose. The U.S. formulation is manufactured to contain 0.3 mg aluminum per dose.

 

Please see full Prescribing Information for BOOSTRIX.

References

  1. Prescribing Information for BOOSTRIX.
  2. American Medical Association. CPT 2022. Chicago: American Medical Association; 2022.